E-posters - Product acceptability and adherence

• 1081 • PrEP use in the HVTN 702 HIV vaccine efficacy trial conducted in South Africa > J. Jackline ODHIAMBO • 1177 • Predictors of PrEP Discontinuation and Refill Delays Among Over 47,000 Clients First Starting PrEP in Kenya, Lesotho and Tanzania: Implications for Programs > J. Jason REED • 1205 • “Men will never take a pill every day if they don’t have to”: Assumptions and realities around acceptability of PrEP among heterosexual men > S. Shawn MALONE • 1220 • Mapping HIV prevention product preferences among adolescent girls and young women at high risk of HIV: Results from a discrete choice experiment in South Africa > Y. Yolande CROUCAMP • 362 • What women want in a multipurpose vaginal ring: Findings from a Phase 1 trial in the U.S. and the Dominican Republic > E. Elizabeth TOLLEY • 377 • Impact of women’s home environment on use of the Dapivirine ring for HIV prevention in MTN-025/HOPE > M. Margaret GICHANE • 484 • Patterns of Adherence Among South African Women in a Phase III Randomized Controlled Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention > E. Erica BROWNE • 888 • Utilization patterns and HIV incidence within the first year of initiation of FTC/TDF for HIV pre-exposure prophylaxis (PrEP) Among Insured Persons in the US > Y. Yohance WHITESIDE • 905 • PrEP adherence is associated with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe > J. Jennifer VELLOZA • 960 • End-users’ hypothetical acceptability of a biodegradable implant to prevent HIV and unplanned pregnancy: Qualitative insights from South Africa and Zimbabwe > S. Sikhanyisiwe NKOMO